title: The lymphangiogenic vascular endothelial growth factors VEGF-C and -D are ligands for the integrin alpha9beta1.
abstract: Mice homozygous for a null mutation of the integrin alpha9 subunit die 6-12 days after birth from bilateral chylothoraces suggesting an underlying defect in lymphatic development. However, until now the mechanisms by which the integrin alpha9beta1 modulates lymphangiogenesis have not been described. In this study we show that adhesion to and migration on the lymphangiogenic vascular endothelial growth factors (VEGF-C and -D) are alpha9beta1-dependent. Mouse embryonic fibroblasts and human colon carcinoma cells (SW-480) transfected to express alpha9beta1 adhered and/or migrated on both growth factors in a concentration-dependent fashion, and both adhesion and migration were abrogated by anti-alpha9beta1 function-blocking antibody. In SW-480 cells, which lack cognate receptors for VEGF-C and -D, both growth factors induced alpha9beta1-dependent Erk and paxillin phosphorylation. Human microvascular endothelial cells, which express both alpha9beta1 and VEGF-R3, also adhered to and migrated on both growth factors, and both responses were blocked by anti-alpha9beta1 antibody. Furthermore, in a solid phase binding assay recombinant VEGF-C and -D bound to purified alpha9beta1 integrin in a dose- and cation-dependent fashion showing that VEGF-C and VEGF-D are ligands for the integrin alpha9beta1. The interaction between alpha9beta1 and VEGF-C and/or -D may begin to explain the abnormal lymphatic phenotype of the alpha9 knock-out mice.
authors.affiliation: Lung Biology Center, University of California San Francisco, San Francisco, California, 94143-2922, USA.
authors.forename: Nicholas E
authors.initials: NE
authors.lastname: Vlahakis
authors.forename: Bradford A
authors.initials: BA
authors.lastname: Young
authors.forename: Amha
authors.initials: A
authors.lastname: Atakilit
authors.forename: Dean
authors.initials: D
authors.lastname: Sheppard
mesh_terms: D000818:Animals; D015153:Blotting, Western; D002448:Cell Adhesion; D045744:Cell Line, Tumor; D002465:Cell Movement; D002478:Cells, Cultured; D003598:Cytoskeletal Proteins / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004591:Electrophoresis, Polyacrylamide Gel; D004730:Endothelium, Vascular / Q000166:cytology; D048049:Extracellular Signal-Regulated MAP Kinases / Q000378:metabolism; D005347:Fibroblasts / Q000378:metabolism; D005434:Flow Cytometry; D006720:Homozygote; D006801:Humans; D047468:Immunoprecipitation; D016023:Integrins / Q000378:metabolism*; D008024:Ligands; D042583:Lymphangiogenesis; D051379:Mice; D018345:Mice, Knockout; D008833:Microcirculation; D051419:Paxillin; D010641:Phenotype; D010750:Phosphoproteins / Q000378:metabolism; D010766:Phosphorylation; D011485:Protein Binding; D034622:RNA Interference; D034741:RNA, Small Interfering / Q000378:metabolism; D014162:Transfection; D042582:Vascular Endothelial Growth Factor C / Q000502:physiology*; D042643:Vascular Endothelial Growth Factor D / Q000502:physiology*
chemical_list: D003598:Cytoskeletal Proteins; D016023:Integrins; D008024:Ligands; C496061:PXN protein, human; D051419:Paxillin; D010750:Phosphoproteins; C496062:Pxn protein, mouse; D034741:RNA, Small Interfering; D042582:Vascular Endothelial Growth Factor C; D042643:Vascular Endothelial Growth Factor D; C113256:integrin alpha 9 beta 1; D048049:Extracellular Signal-Regulated MAP Kinases